UK regulator clears Paramount's $110bn Warner Bros Discovery acquisition

• Britain's Competition and Markets Authority cleared Paramount Skydance's acquisition of Warner Bros Discovery.
• The acquisition is valued at $110 billion.
• The deal still faces legal challenges in the US.
• The deal still faces regulatory review in the UK.
• Warner Bros Discovery reported second-quarter revenue of $8.72 billion.
• Warner Bros Discovery revenue missed analyst expectations.
• Weak advertising sales contributed to the revenue miss.
• Weaker box office performance contributed to the revenue miss.
• Warner Bros Discovery posted a surprise quarterly profit.
• Cost reductions drove Warner Bros Discovery's profit.
• AstraZeneca and Bristol Myers Squibb deny merger talks.
• AstraZeneca shares slid approximately 9% following speculation.

The UK's Competition and Markets Authority (CMA) has cleared Paramount Skydance's proposed $110 billion acquisition of Warner Bros Discovery. This decision marks a significant step in the potential takeover, although the deal is not yet finalized. It still faces additional legal challenges within the United States and ongoing regulatory review in the UK. The acquisition's path forward remains subject to these further assessments.

In separate financial news, Warner Bros Discovery announced its second-quarter results, reporting revenue of $8.72 billion. This figure fell short of analyst expectations, primarily attributed to soft advertising sales and a weaker-than-anticipated performance at the box office. Despite the revenue shortfall, the company managed to post a surprise quarterly profit. This unexpected profitability was largely driven by the company's successful cost reduction initiatives.

In a different corporate development, AstraZeneca and Bristol Myers Squibb have officially denied any ongoing discussions regarding a potential merger. A senior source close to the matter confirmed that no preliminary talks or merger discussions are currently taking place between the two pharmaceutical giants. This denial follows earlier speculation that had circulated, leading to a notable market reaction. AstraZeneca's shares experienced a decline of approximately 9% in the wake of the initial merger rumors.